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Abstract
Viral infectious diseases cause millions of deaths and severe illness all around the
world affecting public health and economics. Viral vaccines are helping to fight against
viral diseases, but current vaccines are expensive and unavailable, especially in poor and
developing countries. When measuring the entire manufacturing processing, the
downstream processing of vaccines is the major cost of production. Our goal for this
research is to develop a low-cost alternative downstream processing platform for new
vaccine manufacturing infrastructures.
We have developed a novel osmolyte flocculation method for viral particles. To
create a platform purification for several types of viral particles, we used two model
viruses: porcine parvovirus (PPV) and Sindbis virus (SINV). PPV is a non-enveloped
virus, one of smallest known mammalian viruses with a diameter of approximately 20
nm. The enveloped virus, SINV, has a size of 48-52 nm. Using mannitol osmolyte
flocculation we demonstrated recovery for both viruses by diafiltration using a micropore
membrane. This will allow easy scale-up to production scale and creates a low cost
platform. Our lab’s previous study showed that osmolyte flocculation was specific to
viruses as compared to proteins which are present as the contaminants in the process.
This preferential flocculation is due to the active hydrophobic surface differences on
viruses and protein surfaces. We studied the effect of membrane pore size on the
recovery of viruses and were able to achieve 60% recovery of infectious PPV using a 0.1
µm and 500 kDa pore size filters. Recovery of infectious SINV was 79% using 0.1 µm
and 96% using 500 kDa pore size membrane filter. Increasing the concentration of virus
results in enhanced recovery of infectious particles, but at high concentration, membrane
pores can get blocked, causing membrane fouling. We also examined the purity of the
recovered virus samples for DNA and protein contaminants. In conclusion, we have
developed a novel purification process that was able to purify and recover infectious viral
particles using large pore size filters, which can decrease overall processing costs.

x

1. Introduction
Infectious diseases have caused an enormous death toll worldwide over the last
century. Viral pathogens cause many of the infectious and severe diseases. HIV/ AIDS
causes 1.6 million deaths every year, and about 36.9 million people are living with the
illness according to the World Health Organization [1]. Vaccines are the best tool to fight
against many viral diseases and can help prevent millions of deaths. According to the
WHO, by 2020 the Global Vaccine Action Plan (GVAP) [2] calls for more equitable
coverage of basic existing vaccines to all communities in the world. These plans are
focusing on increasing current vaccine manufacturing capacity and creating new
manufacturing units in developing countries like India and China. This will be done in
partnerships with the Developing Countries Vaccine Manufacturers Network (DCVMN)
and Global Alliance for Vaccines and Immunization (GAVI) [3]. They will be focused on
finding cost-effective vaccine manufacturing process. The findings from this work will be
able to contribute in research and development for alternative platforms in downstream
processing of vaccine manufacturing. A platform approach for vaccine production can be
a fixed setup and technique for downstream processing that can be applicable to various
types of vaccines with minimal changes in the process and protocol. Downstream
processing deals with the recovery and purification of target viral product for vaccine
formulation.
Recent techniques used in vaccine downstream processing are using traditional
methods such as the combination of several chromatographic steps and ultrafiltration for
the purification of viral products [4]. Chromatographic methods have been used for
proteins and other biological products and are not properly optimized for large biological
molecule purification, like viral products. Ultrafiltration method uses small pore size
membranes that often foul and has a significant pressure drop, which increases
processing cost. In a typical purification process, more than 75% of total production cost
is from downstream processing [5]. Therefore, developing a low-cost platform
downstream process could substantially reduce the cost of a vaccine product. We propose
an alternative approach to chromatography or ultrafiltration, using microfiltration to
1

reduce the membrane cost and the required pressure for filtration. We also plan to apply
this novel process to many different virus types so that this platform approach can be
applied to multiple viral products.
In this work, we have used a novel osmolyte flocculation method, which was
demonstrated in our lab’s previous research publications [6, 7]. This flocculation study
has shown that we can flocculate viruses using naturally occurring compounds known as
osmolytes, which are found naturally in many organisms. After screening several
osmolytes, Gencoglu et.al showed that the osmolyte mannitol was able to flocculate the
model viruses PPV and SINV and was able to remove >80% of the infectious virus
particles with a 0.2 µm filter [6, 7]. The osmolyte mannitol has been FDA approved to be
used in human therapeutics or as the therapeutic agent. Mannitol 20% injection USP drug
is being used as osmotic diuretic for certain kidney conditions, brain damage for reducing
swelling and pressure in brain and eyes [8, 9]. Therefore, as it is naturally occurring and
FDA approved, complete removal of mannitol in the downstream processing is not a
concern. In continuation to this previous study from our lab, we are developing a
downstream processing platform for purification and recovery of viruses using a
diafiltration method.
This thesis begins with a brief background and motivation for these studies. Chapter
2 is the literature review, giving background for viral diseases and vaccines, current
vaccine manufacturing method and motivation and rationale as to why we are looking for
new approaches. In chapter 2, we demonstrated how this scientific study is needed and
can contribute to the need for faster and less expensive vaccine manufacturing platforms.
Chapter 3, contains experimental details and materials used for all experiments.
Chapter 4 shows the results for all experiments with different parameters for PPV and
SINV virus removal, stating results, findings and a discussion of this research. Chapter 5
has the concluding comments about the overall research and includes proposed future
work, which can shed more light on the osmolyte flocculation mechanism.
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In this research, we have shown recovery and purification of PPV and SINV. First,
by studying the effect of different membrane pore size for recovery of viruses, we found
that using larger pore size membrane of 0.1 µm can give 60% recovery of infectious PPV
while decreasing the pore size results in increased recovery. Using diafiltration for PPV
we demonstrated purification of viruses in the retentate from host proteins using HPLC
analysis. We also explored the effect of flocculation time and initial virus concentration.
We have found that using high concentrations of viruses can optimize the recovery of
infectious virus particles, but the high concentration of viruses can lead to membrane
fouling and can increase the pressure requirements for filtration. We analyzed recovered
PPV samples for purity, and we are able to remove 85% contaminant proteins for
purification and only 45% DNA content removal was observed.
For SINV recovery, we compared all parameters listed above for their effect on
recovery of infectious virus particles. Using a large pore size of 0.2 µm gives a 65%
recovery and using a 0.1 µm filter gives 79% recovery. For the purification of SINV, our
current analysis showed only 37% removal of protein contaminant and 49% DNA
removal. Future work will focus on increasing removal of DNA using additional
treatments. All presented results show flocculation of virus particles and recovery of
infectious virus particles using large pore size membranes. These findings show promise
that mannitol flocculation can be applied within the industry to provide low-cost
downstream processing which is safe and scalable.

3

2. Literature Review
2.1.

Viral Diseases, Viruses, and Vaccines

Infectious diseases have, and continue to be, a major threat to public health.
Emerging infectious diseases has threatened human health throughout the history of
humankind. Infectious diseases are caused by the bacteria, viruses, parasites or various
fungi [10]. Viruses cause many diseases that are fatal to their host. Some of the common
viral human diseases and their global effect are shown in Table 2-1.
Table 2-1 Infectious diseases and effects worldwide, [1]

Disease

Virus

Effect

Measles

Paramyxovirus

114,900 measles deaths globally
about 314 deaths every day or 13
deaths every hour (2014)

Human

1.2 –1.6 million deaths every

immunodeficiency virus

year (2014)

Hepatitis B

Hepatitis B virus

780,000 people die every year

Ebola haemorrhagic

Ebola virus

Worldwide 28,646 cases of Ebola

AIDS

fever

virus disease and 11,323 deaths

Dengue and severe

Dengue virus and

390 million dengue infections per

dengue fever

serotypes

year

Influenza A(H1N1)

Influenza virus and

3 to 5 million cases of severe

and A(H3N2)

serotypes

illness, and about 250,000 to

subtypes

500,000 deaths annually

Viruses are pathogens which can replicate only inside the cells of living host
organisms [11]. Viruses can infect all types of organisms such as human, animals, plants
and bacteria. Reports show that there are about 5000 different types of viruses that have
been described at current times, and there could be millions more that we are not yet
aware of [12]. Viruses are typically very tiny, although they range from a few nanometers
4

to a micron in size. The smallest known virus is porcine circovirus, at around 17 nm in
diameter and porcine parvovirus about 20-24nm [13-15]. Other viruses are larger than
some bacteria such as vaccinia virus (230 nm), mimivirus (500 nm) or Pandora virus
(about 1 µm) [12, 15].
Viruses are categorized mainly by their outer layer structure and nucleic acid
content. For the nucleic acid content, viruses encapsulate either DNA or RNA genetic
material [12, 16]. Depending on the genome content of viruses, viruses are classified as
RNA viruses and DNA viruses. RNA viruses comprise about 70% of all the viruses and
can contain single-stranded (ssRNA) or double-stranded (dsRNA) viral content [17].
Depending on the outer layer structure of viruses can be divided into enveloped and
non-enveloped viruses. The encapsulated nucleic acid genome contains a protective
protein layer which forms the capsid [16]. If the virus contains an outer lipid bilayer
membrane around the virus protein capsid, they are called enveloped viruses. This outer
lipid layer around enveloped viruses contains viral proteins which help in binding to the
host cells. Whereas viruses which do not have outer lipid layer are called non-enveloped
viruses. In the case of non-enveloped viruses, the function of binding to the cells is
carried out by the capsid proteins [18]. Due to the large chemical differences in the outer
layer of the virus, developing a processing method which can be applied to different
types of viruses is an important aspect of developing a platform downstream processing
approach.
One of the most efficient methods to date to combat viral diseases is through
vaccines [19], and vaccines are best accomplishments through science for the benefit of
public health [20]. Viruses which causes infectious diseases can be used to fight against
diseases in the form of viral vaccines. The goal of the vaccines is to help the human body
to form immunity against a viral infection by producing an antibody response [21]. This
allows the body to fight against the virus when the body encounters it, before the
infection taking hold in the body. During 2000-2014, measles vaccination prevented 17.1
million deaths. Polio cases from the world have been decreased by 99% because of
5

vaccines. Influenza vaccines save millions of people from high influenza complications
and can provide reasonable protection in adults upon vaccination worldwide [1].
The first vaccine by Edward Jenner for smallpox was able to eradicate smallpox [22,
23]. Also, the first attenuated vaccine developed by Louis Pasteur for rabies by
attenuating rabies virus in the laboratory [24]. Discovery of the first vaccine was the
landmark achievement as it shows that using the virulent virus as a vaccine can help to
fight against the disease. Since Jenner’s discovery and Pasteur’s vaccine, the advances in
immunological studies have helped us to understand how the immune system can help to
fight against diseases using vaccines [22, 23]. There has been continuous research going
on to find improved technology for improving quality and quantity of vaccine production.
Even with all the recent advancement in immunology and vaccine manufacturing, there is
no equality in distribution and availability of vaccines in industrialized developed
countries as compared to developing and poor countries [25]. The current global
vaccination plans focus on the public health within developing and poor countries which
requires wide and easy access to large quantities of vaccines at affordable cost. One of
the major strategic goals of the WHO includes more focus on the research and
development in vaccine manufacturing in developing and middle-income countries [2].
There are about 22 millions of children in poor and developing counties which are still
not protected against viral diseases due to lack of vaccination availability [26]. Global
coverage for basic vaccines shows that there is need of a major supply of vaccines needed
in south-east Asia, Western Pacific region and African region. Figure 2-1 shows the
global coverage of current basic vaccines. Out of this total global coverage for vaccines,
Table 2-2 shows the areas affected most by low coverage of immunization.

6

Table 2-2 Global vaccine coverage by April 2015, [1]

WHO along with DCVMN and GAVI are working together to provide access to
vaccines in poor and developing countries like India, China, and the African Union. So,
emerging and developing countries are looking for affordable vaccine manufacturing
processes so they can start their own vaccine production units [27].

Figure 2-1 Global immunization coverage WHO [1]

Unlike other chemical drugs, vaccines are made from biological agents which are
susceptible and can be compromised during various manufacturing processing stages. At
7

every stage of vaccine processing, it needs strict regulations for safety and quality
monitoring in the manufacturing. There are various regulatory authorities for maintaining
regulations for vaccines such as Food and Drug Administration’s (FDA) Center for
Biologics Evaluation and Research (CBER) in the United States, the European Medicines
Evaluation Agency on behalf of WHO, and the National regulatory authority (NRA). The
regulatory agencies focus on safety, efficacy and purity. In the exploration of new virus
purification methods, the regulatory restrictions on safety, efficacy, and purity must be
kept in mind.
We are pursuing methods to reduce the cost of viral vaccine manufacturing so that
distribution to GAVI countries can be greatly increased. The focus of our research is to
create an economical vaccine manufacturing processes using FDA approved osmolytes as
preferential flocculants while keeping the regulatory requirements of safety, efficacy and
purity in perspective as a platform approach. Also, the approach should not be limited to
lab scale and should be easily scalable for large scale production. Our goal is to establish
a low-cost vaccine manufacturing process so that vaccines can be available at reduced
rates in poor and developing countries.

2.2.

Types of Vaccines
Traditional vaccines contain part or all of a disease-causing agent. Many of the

vaccines are based on viruses. There are three main types of vaccines, live/attenuated,
inactivated and subunit vaccines. There is a sense of balance between protection and
efficacy when choosing which vaccine type to pursue.
Live attenuated vaccines contain the whole viruses in an attenuated form which are
weakened by passing through multiple cell cultures so that it cannot cause a serious
disease in humans. They provide a strong immune response against the disease and can
provide lifelong immunity with one or two doses. Live attenuated vaccines are successful
against human viral diseases, however as this vaccine type contains live viruses that are
very similar to the natural infectious virus, there can be some safety issues. Live
8

attenuated vaccines can become virulent or mutate at some point and cause the disease [3,
28]. There have been cases reported about live attenuated polio vaccine which was found
to contain wild-type polioviruses [28, 29]. Report from 2009 showed that the polio
vaccine paralyzed several children in 2007, 2008 and 2009 [1].Therefore, the quality and
purification processing during live vaccine manufacturing is critical to minimize the
downsides of live vaccines. The examples of live attenuated vaccines are measles,
mumps, rubella (MMR combined vaccine), rotavirus, varicella (chickenpox), influenza
(live attenuated influenza vaccine) [30]. Also one of major limitation with the live
attenuated vaccine is storage, as these vaccines need to be refrigerated to keep the
potency and effectiveness. This leads to a higher cost vaccine. Developing countries and
poor countries lack widespread refrigeration. So, considering these are important factors,
manufacturers from developing countries are looking to manufacture vaccines in their
own region so it will minimize the cost of vaccines and avoid shipping overseas from
other countries.
Inactivated vaccines are produced by using viruses that cannot replicate due to
chemical, heat or radiation inactivation methods [31]. Inactivated vaccines typically
create a weaker immune response than live attenuated vaccines, so inactivated vaccines
are given in several dosages or booster shots may be required to keep immunity against
the disease [32]. The high number of dosages leads to high immunization costs in areas
where there are no health care facilities available, specifically in poor and developing
countries. Inactivated polio (IPV) and hepatitis A (HAV) are examples of inactivated
vaccines [33].
Instead of using the whole virus for vaccines, subunit vaccines contain only part of
an antigen from the virus, which activates an immune response against it. Subunit
vaccines are typically expressed recombinantly in bacterial cells, decreasing the cost and
complexity of manufacturing, as compared to mammalian or insect cells that are needed
for live-attenuated and inactivated vaccines [32]. Hepatitis B, influenza (injection), and
haemophilus influenza type b (Hib) are examples of subunit-conjugate vaccines [33, 34].
As inactivated vaccines may need several dosages, it may be challenging to provide
9

vaccination in the areas where people do not have continuous access to health care
services and are unable to get all the dosage or booster shot in a timely fashion [35].

2.3.

Model Viruses

To study viral purification and virus recovery and propose a universal platform that can
be applied to all types of viruses, we need to select suitable types of viruses which can be
a good model for viruses used as human therapeutics. There are two major types of
viruses, enveloped and non-enveloped viruses. Non-enveloped viruses do not contain an
outer phospholipid coating; there is only a protein capsid that surrounds the viral nucleic
acids. Enveloped viruses contain an outer envelope around the viral capsid which is made
of phospholipids and proteins or glycoproteins [36]. We wanted to study both types of
viruses, i.e. enveloped and non-enveloped virus as presence or absence of envelope can
affect the flocculation studies significantly.
For our virus purification study, two viruses were selected as models; the nonenveloped PPV and the enveloped SINV. Parvoviruses cause the variety of diseases in
vertebrates and arthropods and have been isolated from mammals like humans, dogs,
cats, rodents, cows, and pigs [37]. Parvoviruses are the second smallest known
mammalian virus at 18-26 nm in diameter and contain single-stranded DNA [13, 14].
PPV is a common cause of reproductive failures in swine [38]. PPV is a good model
virus for human B-19 parvovirus, hepatitis A, and poliovirus. B-19 parvovirus is
widespread in human and causes erythema infectiosum skin rash illness and it is more
common in children than adults (CDC) [39]. We use PPV as a model virus because it is
small, making it difficult to separate by using size-based methods and represent nonenveloped, DNA virus type. PPV is resistance to heat and is chemically inert as it shows
resistance to physical or chemical treatment [40-42].
Our enveloped virus model, SINV, is an arthropod-borne virus from the Togaviridae
family [15]. It is a single-stranded RNA virus with an icosahedral capsid and contains a
protein envelope made of glycoproteins. SINV causes epidemic polyarthritis and rash
sickness commonly known as Pogosta diseases in humans which may lead to prolonged
10

arthritis [43]. SINV is one of smallest enveloped virus with size about 50-60nm [14, 44].
SINV is a model virus for eastern and western equine encephalitis viruses which causes
infection in human and horses and are widespread deadly diseases. As it contains an outer
envelope layer, surface properties of SINV such as hydrophobicity and charge play a
major role in different purification methods.
As successive research in virus purification with various viruses has provided the
detailed understanding of the viral structures and how properties of viruses such as size,
isoelectric potential (pI), virus hydrophobicity, and the presence of envelope can alter
purification processes [4, 45]. Viruses possess a pH dependent surface charge in polar
media such as water or buffer. This surface charge determines the absorption of virus
particles on surfaces, and it can govern the colloidal behavior of viral particles [46, 47].
One measure of colloidal charge is the isoelectric point (pI). The pI is the pH at which
surface charge changes its sign or acts as a neutral molecule. The isoelectric point (pI) for
PPV is about 5.5 [48], and the pI for SINV is about 4.4 [49].
For our studies for flocculation with osmolytes, the hydrophobicity of viruses is an
important property as flocculation is hypothesized to be based on the preferential
hydration and hydrophobicity difference between viruses and proteins [6, 7].
Hydrophobic interactions are the forces between two non-polar groups which attract two
particles together. Non-polar molecules tend to form intermolecular contacts to reduce
their surface contact with polar molecules, such as water. In the case of our hypothesis,
viruses are hydrophobic in nature and contain water shell around outer surface in an
aqueous solution. Upon removing the water surrounding the virus particles with
osmolyte, viruses tend to attract each other and forms aggregate. This effect is explained
on proteins by C.J. VanOss, 1995 through precipitation of proteins by dehydration
method. By removing water around particles, their surface at the interface becomes more
hydrophobic. This changes the normal repulsive forces between particles and turns them
into the net attraction forces causing particle aggregation [50]. Studies in the literature
have shown the presence of hydrophobic areas on the virus surfaces.
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Both enveloped and non-enveloped viruses contain sites for fusion proteins on their
outer surface which helps the attachment to the host cell membranes. In the study by
Badani et al. 2014, it was shown that viral fusion proteins or viral membranes contain
hydrophobic segments. It has shown virus attachment to the host cell is related and driven
by the hydrophobicity of viral binding proteins or viral membrane surface [51]. As per
their hypothesis, the virus entry inhibition is explained by the physical chemistry of
hydrophobicity i.e. active hydrophobic sites and patches on different sites of virus surface
(e.g. class I, class II and class III fusion proteins on viruses) on the viruses as well as on
the cell membranes. The Wimley–White interfacial hydrophobicity scale is used to
determine the hydrophobicity range based on the interfacial hydrophobic interactions
[52]. This method determines the transfer free energy of the amino acids along with
peptide sequence. The transfer free energy is a scale of the propensity for amino acids to
transfer from water to phosphatidylcholine interface [51]. Badani et al. used this WimleyWhite interfacial scale to score hydrophobicity based on interfacial hydrophobic
interactions of viruses. On this scale, a positive score indicates the presence of
hydrophobic interaction based on peptide sequence and hydrophobic interactions. Zero
point on scale divides the peptide sequence regarding free energy into hydrophobic or
not. They have shown positive scores for Dengue virus, West Nile virus, murine hepatitis
virus, respiratory syndrome coronavirus, influenza virus, hepatitis C virus [51]. This
demonstrates that viruses have active hydrophobic sites present on their surface. This
study was showed for all enveloped viruses. Another study has shown the presence of
hydrophobic sites on non-enveloped Reovirus membrane [53].
Our past work on PPV concluded that both hydrophobicity and charge play a major
role in the binding of porcine parvovirus, and we have shown that viruses are more
hydrophobic than proteins thus hydrophobicity of viruses plays an important role in
flocculation of viruses using osmolyte [6, 7].
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2.4.

Vaccine Manufacturing
Current manufacturing methods for vaccines, related therapeutics, bioproducts are

very product specific. Traditionally, vaccines were prepared using embryonated chicken
eggs or animals. For example, Edwards Jenner’s first vaccinia was inoculated in cows
[22, 23]. More recently, the seasonal flu vaccine is prepared using fertilized embryonic
eggs, which usually takes a long time to prepare [54]. Egg-based methods are a labor
consuming method, requires a significant amount of fertilized eggs at one time and is
highly susceptible to bacterial contamination. Additionally, individuals that are allergic to
eggs may not receive this type of vaccine.
Since the development of new methods and research in vaccine manufacturing, cellbased vaccine manufacturing processes are being used to produce vaccines. Cell-based
vaccine manufacturing was first done by using in vitro cultivation with non-neural human
cells by Enders in 1949 for poliovirus and then in 1955 by Salk for inactivated polio
vaccine using monkey kidney cells [55]. From that time, industries are significantly
looking to use cell culture-based vaccine production using mammalian cells. Cell culture
based vaccine manufacturing methods can be much safer, as processing takes place in
closed systems, the chances of contamination are reduced [56]. The vaccine regulatory
authorities encourage cell culture based vaccine manufacturing and this method can be
scaled up for emergency large production requirements. The production time for cell
culture-based vaccine manufacturing is reduced to half as compared to traditional vaccine
manufacturing using embryonic eggs based method [54]. However, using cell culturebased vaccine manufacturing produces less virus, and the volumetric yield is low [54].
This requires large volume bioreactors to achieve the desired yield of viruses, which adds
up to higher capital investment for the production plant. The relatively higher
manufacturing cost may translate to more expensive vaccines. New research and
development teams are focusing towards developing current vaccine manufacturing
processes so that the cost of manufacturing and vaccines will be more economical. Our
focus is to develop alternate low-cost vaccine manufacturing platforms to create an
economic vaccine manufacturing process.
13

2.4.1. Upstream and Downstream Processing
Vaccine manufacturing process is classified into two different stages, upstream and
downstream processing, as shown in Figure 2-2. Upstream processing comprises of
growing and cultivation of cells, infecting the cells with the virus of interest and
harvesting of cell lysates. Once cells are infected completely, and viruses are reproduced,
cell lysis is typically performed through homogenization or adding non-ionic detergents,
like Triton X [57, 58]. Next, cell debris is removed through clarification, which can be
carried out with centrifugation, or filtration methods [59-61]. Once the clarified solution
is obtained, it proceeds to downstream processing, involving purification, concentration,
and polishing.

Figure 2-2 General outline for Vaccine manufacturing with upstream and downstream processing,
upstream processing includes cell growth, virus production, and downstream processing deals
with clarification, purification, and recovery of viruses.

After harvesting viruses from the host cells, downstream processing deals with the
purification and concentration of the viral products. Purification is aimed at removing
contaminating host cell proteins, DNA, and impurities introduced during the purification
14

process. Using a variety of physical properties as size, isoelectric potential (pI), and the
hydrophobicity different methods are selected for purification [4, 45]. There are several
methods for virus purification. Commonly used methods for virus purification are
ultrafiltration and chromatography [4, 62-65]. Membrane-based ultrafiltration is typically
used for partial purification and chromatography is usually used for final product
purification. Other purification methods are depending on the viral size and properties
such as ultracentrifugation which uses density based separation, precipitation by
chemicals, PEG, flocculation using salts, and membrane absorption which uses charge
based properties of viruses [60, 66-69].

2.4.2. Ultracentrifugation
One of the methods employed for virus purification is ultracentrifugation. Density
gradient centrifugation using cesium chloride or iodixanol gradient is one of the wellknown and established method for the virus in preclinical studies [4, 66, 70]. Also, there
are concerns over CsCl toxicity and its complete removal after viral purification can be
challenging. While ultracentrifugation leads to very pure products, the lack of scale-up
options makes it undesirable for manufacturing. This method can be used for limited
sample separation by using ultracentrifugation, which uses very high rotational speeds.
The purification is based on the different buoyant densities of virus particles and
contaminants. Ultracentrifugation will even separate full from empty viral particles [71,
72]. This method is mostly used in a lab due to the lack of industrial scale
ultracentrifuges. A CsCl density gradient was used for the purification of adenovirus (Ad)
and adeno associate virus (AAV) [66, 73], showing lab-scale purification for Ad and
AAV. A recent study showed a 60% yield for CsCl and a 65% infectious units recovery
for an iodixanol based AAV purification method [74]. While yield and purity can be high
with ultracentrifugation, the lack of scale-up options makes it unfeasible for vaccine
production.

2.4.3. Chromatography
In the biopharmaceutical industry, chromatography is the most commonly used
separation and purification technology due to its easy applications to all products and its
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high resolution. Chromatography separation is based on the different interactions
between viruses and the surface of chromatographic beads such as size based (size
exclusion chromatography), charge based (ion exchange chromatography), and
hydrophobicity based (hydrophobic interaction chromatography HIC, reverse phase
chromatography). Ion exchange chromatography is charge based separation depending on
the interactions between charged particles and ionic ligands on the chromatography
beads. Therapeutic molecules bind to the column under low salt condition and elution is
done using high salt gradient because the ionic interaction is disrobed by the high ionic
strength solution. Hydrophobic interaction chromatography is based on binding of
particles to the hydrophobic surfaces depending on the hydrophobicity of particles. In
HIC, particles are loaded in the high salt buffer which promotes the hydrophobic effect
and drives adsorption with solid support. The separation works with low salt gradient
based on the difference in hydrophobicity as a result of desorption from resin.
Several studies have shown that various chromatography methods such as ion
exchange, size exclusion chromatography, affinity chromatography in combination with
multiple chromatographic steps in series or with membrane filtration can be used for
virus purification and recovery [64, 75, 76]. Bead chromatography methods have a high
surface area in the internal pores of the beads, and the capacity of the resin subject to the
diffusion of molecules into the pores of the beads. This poses a big limitation for the
purification of large molecules that either cannot enter the pores or quickly plug the pores
upon binding. One newer method to overcome the problem of bead chromatography is
membrane chromatography. In membrane chromatography, all of the surface area is
accessible by convective flow and does not rely on diffusion into pores [77]. This allows
for the much more accessible surface area by large biomolecules. However, there is still
low overall surface area per volume with membrane chromatography. It has therefore not
been implemented as much as originally thought. In Table 2-3, we have shown some of
the work which uses the chromatographic technique as primary purification method with
or without the combination of other methods.
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Table 2-3 Literature review for some of the chromatographic techniques used in purification of
viruses
Study
3 step chromatographic
process for Influenza type
A & B purification
Purification of Rotaviruslike particles (RLP’s)

Method
Anion exchange chromatography,
benzonase treatment and final size
exclusion chromatography

Results
68% virus yield and

Anion-exchange membrane
chromatography

46% global yield,

using chromatography
Purification and
characterization
(immunogenicity) of

Reference
[78]

98% DNA removal
[75]

100% DNA removal,
98% HCP removal

Anion exchange chromatography
Retained immunogenicity
(immunoblotting)

norovirus (NoV) VLPs.

Final yield is not

[79]

mentioned, 90%
purification w.r.t.
DNA content and

Combined ultrafiltration

Ultrafiltration using 300,000

HCP
54% final PRRSV

and chromatography

nominal molecular weight limit

recovery, 96%

process for Porcine

(NMWL) membrane followed by

cellular and medium

reproductive and

heparin affinity chromatography

proteins removal

Recovery of porcine reproductive

50% recovery of

and respiratory syndrome (PRRS)

PRRSV

[80]

respiratory syndrome
virus (PRRSV)

[65]

virus using ultrafiltration and anion
exchange chromatography
Purification of
Adenovirus using 2 step
anion exchange

Set of 2 anion exchange
st

chromatography (1 Q Sepharose,
nd

2 Source 15Q)

40% infectious unit

[81]

recovery of
Adenovirus and 99%

chromatography

purity

Purification of

Primary purification using anion

80% virus particles

Adenovirus using

exchange chromatography and final

recovery, 99% purity

combined

polishing using size exclusion

chromatography

chromatography

technique
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[82]

Influenza A virus

Size-exclusion chromatography

Final product yield of

recovery and purification

(SEC) and anion-exchange

52%, and 19-fold

using 2 chromatography

chromatography

HCP reduction, 500-

steps

[83]

fold DNA content
reduction

As discussed earlier chromatography offers advantages for high purification and
product yield but it has several disadvantages. Chromatography is mainly used for protein
purification and has been adapted for virus purification. There is no platform
chromatography method which can be used for viruses because of different structure,
size, and charges of viruses. Also, the concentration of viruses cannot be done solely
using chromatographic technique [84]. So there is a need for downstream processing to
look for new platform approach other than using chromatographic techniques for viral
vaccine processing.

2.4.4. Filtration
Filtration has been an integral part of biotechnology, and it is used as both a
concentration and separation method for viral products [68]. Membrane based separation
and purification methods are typically applied as size-based separations. This approach
can provide good separation and purification and is easy for scaling up at commercial
scale with high throughput. Current membrane based separation methods typically use
ultrafiltration membranes. Diafiltration using ultrafiltration membranes has been widely
used in virus DSP for concentration and separation as described in the literature [68, 85,
86]. Ultrafiltration membrane range in pore size from 0.5 to 1000 kDa MWCO [87].
Filtration methods can be operated in two types of flow, normal flow filtration (NFF)
(also called dead end filtration) and tangential flow filtration (TFF). In NFF, flow is
perpendicular to the membrane and particles larger than the membrane pore size are
typically withheld by the membrane, while smaller particulates pass through the
membrane. This mode is usually used when the product of interest passes through the
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membrane. This is because the larger size particles are retained on the top, causing a
buildup of particles on top of the membrane, which leads to cake formation on the
membrane, increased sieving and increased transmembrane pressure [88, 89]. To avoid
this, TFF uses the tangential flow of fluid with applied pressure. As in NFF particles
larger than pore sizes are retained and smaller particulate pass through the membrane,
while tangential flow sweeps the retained particles to avoid buildup on the membrane. In
operation of TFF, once a steady-state is reached, the transmembrane pressure stays
relatively stable. Membrane-based TFF is applicable in downstream processing of many
biologics and viruses. Low pressure and cross-flow pattern of TFF with hollow fiber
membranes provide less stress on particles than dead end filtration and promotes gentle
treatment for virus particles and proteins to retain their structural activity [5]. However,
there is still possibly a flux decline due to fouling and shearing of the particles, which
could cause virus inactivation. To avoid this disadvantages using membrane-based
separation method, we are looking at the combination of flocculation and membrane
filtration methods so that we can use large pore size membranes for virus purification and
recovery.
TFF using the ultrafiltration membrane for concentration and purification is one of
the most common purification steps before or as a final polishing step [90-93]. It was
shown that the membranes with smaller pore sizes than the virus particles can be used for
concentration and purification of viruses [92]. Using small pore size ultrafiltration
membranes for virus/ viral vector recovery was performed in several studies as shown in
Table 2-4.
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Table 2-4 Tangential flow filtration studies for various virus/ VLP/ vectors from the literature
Study Virus

Size

Method, Results

Reference

HIV-1-derived

80-130 nm

TFF (300 kDa), 100% recovery

[90, 94]

lentiviral vector

TFF (100 kDa), 100% recovery
TFF 100 kDa+ 5 hour centrifugation 26000g, 18%
recovery*
TFF 100 kDa+ 2 hour centrifugation 76000g, 94%
recovery*
* transducing units recovery after centrifugation

Aedes aegypti

20-30 nm

TFF using ultrafiltration membranes, 30 kDa and 50

densonucleo-

kDa able to retain virus particles while using 100

Sisvirus

kDa and 300 kDa particles can be seen in permeate

Influenza A

80-120 nm

Screening of ultrafiltration membranes100 kDa, 300

virus (Human

kDa, and 0.1 μm, 0.2 μm MWCO membranes,

virus Type A)

results showed 300 kDa membrane gives optimal

[91, 95]

[92]

recovery and 84% protein removal
Flavivirus
pseudoinfectious
virus

40-60 nm

2 step purification method with TFF (using 100 kDa

[96, 97]

and 500 kDa TFF cassette) followed by anion
exchange chromatography. TFF with 100 kDa gives
recovery 80% followed by 54% recovery in AEX

Parvovirus

22-26 nm

Purification and recovery using high-performance

Minute Virus of

tangential flow filtration, optimal virus exclusion

Mice

observed with 50 kDa and 100 kDa membranes, 300

[98]

kDa membrane not effective in retaining virus
particles
HIV VLP

120 nm

Recovery and concentration of HIV VLPs using 500

[99]

kDa hollow fiber on automated TFF system
Viral

Adenovirus

Large scale (500 liters) recovery and concentration

adventitious

70-90 nm,

of 4 viruses using 100 kDa MWCO hollow-fiber

agents (AAs)

Parvovirus 18-

filters:

26 nm,

Human adenovirus type 5, 84 % recovery

Herpesvirus

Bovine parvovirus, 93 % recovery

110 nm,

Bovine herpesvirus 4, 85 % recovery

Simian virus

Simian virus 40, 88 % recovery

45 nm
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[100]

These studies have shown using ultrafiltration membranes of size ranging 30kDa to
100kDa can be utilized for purifying viral particles based on the size of particles.
Optimum recovery was shown in the retentate while removing host cell proteins. Pore
plugging due to pore size variability in membranes, plugging of proteins, small viral
fragments reducing the flow rate, declining membrane reflux, and requirements of high
throughput pressure system is shown in many studies [91, 96, 98, 99]. As described
above regarding the current ultrafiltration methods, to overcome challenges
microfiltration can be a better option. As disadvantages of ultrafiltration add up to high
processing cost as the high-pressure system is required. Also, it can increase the
processing time and membrane washing steps are required, and there will be reduced
flow rate [101]. We are using large pore size membranes which will eliminate this
challenges and will be able to provide a cost effective method.

2.4.5. Precipitation and Flocculation
Precipitation is commonly used method for protein concentration [102]. It is
typically performed by the salting out of proteins with the high concentration of salts
such as ammonium sulphate ((NH4)2SO4) or sodium sulphate (Na2SO4) [102, 103].
Precipitation by polyethylene glycol (PEG) has been used for virus concentration and
purification for viruses such as murine leukemia virus [104] and influenza virus at a low
concentration of PEG [105]. Several PEG-based precipitation experiments have shown
that PEG precipitates proteins [106-108] when used at greater than 5% concentration.
Therefore, higher PEG concentrations can concentrate, but not purify virus. While lower
concentrations of PEG can purify virus by precipitating virus and not proteins, salt
precipitation can precipitate proteins and can affect the virus integrity [102]. Flocculation
using polyaluminum chloride has shown flocculation of bacteriophages due to influence
on the surface characteristics of phage particles, but this method also affects viral activity
and shows inactivation of bacteriophages [109]. This flocculation in the presence of
polyaluminium chloride happens because at that pH the surface charge of phages
becomes neutral and electrostatic forces becomes insignificant which drives particles to
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aggregates. The study for selective precipitation of Immunoglobulin G (IgG) and proteins
showed that different concentration of ammonium sulfate for precipitation. The
Concentration of 2.5 M ammonium sulfate found to precipitate bovine serum albumin but
not IgG [110]. Table 2-5 shows some methods from literature for precipitation of
viruses.
Table 2-5 Various precipitation method used for purification and recovery of viruses

Virus

Precipitation method

Reference

Ocean Viruses

Recovery using FeCl3 flocculation method with

[111]

tangential flow filtration, 90% recovery.
Enterovirus &

Recovery using ammonium sulfate (low pH 3.5)

MS2

precipitation method with centrifugation, 70%

bacteriophage

enterovirus recovery, 84% bacteriophage recovery.

Recombinant

Recovery and purification PEG precipitation (PEG
6000) using centrifugation,
90% recovery in sediment

[113]

Bacteriophage

Purification using salt precipitation with MgSO4,
NaCl, and PEG
PEG 6000+ NaCl: 92% recovery
PEG 6000+ MgSO4: 91% recovery

[102]

PPV

Virus removal using osmolyte mannitol and alanine
flocculation method followed by microfiltration, 80%
removal of PPV
Virus removal in the presence of osmolyte mannitol as
flocculating agent and removal using microfiltration,
96% removal of SINV with mannitol

[6]

VLP from yeast

[112]

homogenate

SINV

[7]

Precipitation or flocculation is typically followed by centrifugation or filtration to
either remove or recover the flocculated/precipitated species. Flocculation prior to
filtration is highly desirable as it can reduce the membrane fouling, increase product
recovery and decrease the number of steps for final product purification [114, 115].
While in Table 2-5, it is shown that FeCl3, MgSO4, NaCl, and PEG have been used for
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the flocculation of viral products, previous work in our lab has demonstrated that a class
of natural compounds called osmolytes can flocculate virus particles without affecting
proteins.
Our lab’s previous studies have explored a variety of osmolytes for flocculating the
model non-enveloped and enveloped viruses, PPV and SINV [6, 7]. Different osmolytes
and concentrations were screened for their ability to flocculate and remove the virus with
a 0.2 µm filter. The osmolytes mannitol, alanine, glycine, trehalose showed the removal
of PPV of greater than 80% (Figure 2-3-A). Comparing the size of the virus, which is
about 20 nm, to the 0.2 µm filter, this results supports the hypothesis that the osmolytes
can flocculate virus particles. For the enveloped virus SINV, mannitol, glycine, betaine,
and proline were able to remove >80% of the virus with a 0.2 µm filter (Figure 2-3-B).
Mannitol was able to remove 98% of the SINV in solution.
Studies were carried out to conclude the effect of ionic strength and pH on the
removal of PPV and SINV. Increasing the ionic strength of solution by addition of salt
0.2 to 0.6 M NaCl to 1M mannitol decreased the PPV removal, possibly because the
addition of salt affected the viscosity of the solution, decreasing flocculation. Increasing
the ionic strength of SINV solution did not change the removal. While in the case of the
control studies using water and PBS [6, 7], increasing the ionic strength increased
removal, likely due to the salting out effect which also affects proteins. Effect of pH on
the virus interaction for osmolyte flocculation has been shown for PPV. The interaction
between zwitterionic osmolyte compound and PPV and SINV is favorable near the virus
pI [6, 7]. When the virus is negatively charged above its pI, there are ionic repulsive
forces which likely decrease virus aggregation.
Shear stress studies were carried out which includes incorporation of high stress
during virus flocculation [6, 7]. Results showed that applying high shear to the
flocculated samples reduced the removal of viruses as stress is breaking the flocs.
Keeping the disturbances to the samples to the minimum extent during filtration can help
to maintain the flocculation and optimize virus yield, demonstrating that pump choice
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and filtration configuration will be important to the industrial implementation of this
method.
Looking at the data for both PPV and SINV, it was determined that mannitol was the
flocculant that had high removal for both viruses. So, we decided to use mannitol as our
flocculating osmolyte for further studies to demonstrate recovery and purification. Since
we were unable to recover the virus from the membrane surface using dead end filtration,
we also changed the filter configuration to leave virus in solution and relieve the need to
recover the virus from the membrane filter.
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Figure 2-3 Screening of osmolytes, salt, PEG, control tris buffer and water for removal of PPV
and SINV, virus removal was calculated using flocculated virus titers before filtration and after
filtration. All Experiments performed using 0.2 µm 96-plate filtration, flocculation time allowed
was 2 hours [6, 7, 116]. Images taken with permission from publisher and author, permission
attached in the appendix.
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2.5.

Osmolytes
Osmolytes are naturally occurring compounds found in the cells of many organisms,

including mammalians and marine animals. As the name osmolyte suggest, they help in
maintaining osmotic pressure in cells by pulling water towards them, especially marine
animals who live in high salt environments [117]. This mechanism of osmolytes helps to
control the cell volume by changing the water content of the cells. Osmolytes are also
known to stabilize the proteins. There are two types of osmolytes, depending upon their
action with the proteins, protecting and denaturing. The categories of osmolytes are Noxides, amino acids, sugars and polyols, and denaturing, which includes urea and
guanidine hydrochloride [118]. Protecting osmolytes force protein folding by excluding
the protein backbone from water molecules as they do not bind directly to the proteins
while denaturing osmolytes causes the proteins to unfold by binding to the protein
backbone. Naturally occurring osmolytes help in stabilizing proteins against denaturing
stresses by disruption of unfolded state of proteins in the presence of osmolyte [117, 119]
Although there is no universal theory behind the mechanism of osmolytes
interaction, work by Street and Bolen has shown that the strength of osmolytes to interact
with the protein backbone may explain osmolytes ability to stabilize proteins [117]. In
their study, the ΔG, or Gibbs transfer energy of transfer, was measured for the protein
backbone being transferred from water to a 1M osmolyte solution. Protecting osmolytes
have a positive ΔG free energy of transfer, demonstrating that osmolytes interact
unfavorably with the protein backbone. This suggests that the osmolytes do not bind to
the protein backbone. Instead, they are binding to the water around the protein surfaces
resulting in a depletion of water around the protein backbone. In contrast, denaturing
osmolytes have a negative ΔG transfer energy, demonstrating a favorable interaction
between osmolytes and protein backbone. This suggests that the mechanism of protein
denaturation by denaturing osmolytes is due to direct binding of the osmolyte to the
protein backbone. We hypothesize that the ability of protecting osmolytes to control the
water structure around the proteins can be used as a potential flocculant for the viruses as
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virus capsids are made of proteins. Our hypothesis is based on the preferential hydration
mechanism of osmolytes. As due to active hydrophobic surface on virus particles, when
water is removed around the viruses they tend to aggregate with each other. The addition
of osmolyte to virus solution will structure water around the viruses, removing water
around can help the viruses come together to form the bigger flocs due to the
hydrophobicity of viruses [6, 7, 116].
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3. Materials and Methods
3.1.

Materials

Mannitol (C6H14O6), thiazolyl blue tetrazolium bromide (MTT), sodium dodecyl
sulphate (SDS) hydrochloric acid (HCl) were purchased from Sigma-Aldrich (St. Louis,
MO). Reagents for cell culture, minimum essential medium (MEM), phosphate-buffered
saline (PBS, pH 7.2), 0.25% trypsin/EDTA, and penicillin/streptomycin (pen/strep) and
gentamicin (gentamicin sulfate) were purchased from Life Technologies (Carlsbad, CA).
Tryptose phosphate broth (TPB) was purchased from VWR supplier (Radnor, PA). Fetal
bovine serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA). We
used NanoPure water with a resistivity of >18 MΩ.cm (Thermo Scientific, Waltham,
MA) for all the solution preparation and were sterile filtered using 0.2µm syringe filter
(Nalgene, Rochester, NY) or with a 0.22 µm bottle top filter (Millipore, Billerica MA).
For the HPLC study, HPLC grade acetonitrile 99.93% and trifluoroacetic acid (TFA)
≥99.0% were purchased from Sigma-Aldrich (St. Louis, MO). For TEM work, propylene
oxide, glutaraldehyde (Grade I, 70% in H2O), sodium cacodylate (BioXtra, ≥98%), lead
citrate (purum, for electron microscopy) and agarose gel (Type I, low EEO) were
acquired from Sigma-Aldrich (St. Louis, MO). The embedding kit for preparing samples
for electron microscopy EMBed-812 embedding kit, osmium tetraoxide 2% aqueous
solution and uranyl acetate were obtained from Electron Microscopy Sciences (Hatfield,
PA).

3.2.

Cells and Viruses

3.2.1. Cell culture
Porcine kidney (PK-13) cells are grown and cultured in (MEM) completed with 10%
FBS and 1% pen/strep. Baby hamster kidney (BHK) cells are grown and cultured in
MEM completed with 10% FBS, 5% tryptose phosphate broth (TPB) and 1% gentamicin.
To maintain the cells, they were washed in PBS, followed by addition of 3 ml of trypsin
for removing the attached cells from the flask wall. PK-13 cells are more adherent to the
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flask wall, so after waiting 10 minutes we hit the flask manually to remove cells from
wall. BHK cells are easily detached from the flask wall in 3-5 minutes. After cells detach
from the wall, trypsin was neutralized using equal quantity of completed media. Cells
were separated from trypsin by centrifugation in a Sorvall ST16R Centrifuge (Thermo
Scientific, Pittsburgh, PA) at 1500rpm for 3 minutes. PK-13 cells were propagated every
3 days when the confluency reached >80% and a split ratio of 1:5. BHK cells were
propagated every day with a split ratio of 1:3. All cells were maintained at 37°C, 5% CO2
and 100% humidity.

3.2.2. Virus preparation and titration
PPV virus was propagated in PK-13 cells. PK-13 cells were seeded at a density of 6
x 105 cells/flask and incubated for about 24 hours, with the goal of 90% cell confluency.
The media was removed, and the flasks were inoculated with 1 ml of PPV at a
concentration of 103 MTT50/ml diluted in PBS, 3% FBS and 1% pen/strep. After 1.5
hours, 9 ml of fresh media was added to the flasks and the infected cells were incubated
for five days. Flasks were frozen at -20°C, scraped and clarified using centrifugation at
5000 rpm for 15 minutes at 4°C using Sorvall ST16R Centrifuge (Thermo Scientific,
Pittsburgh, PA). The clarified virus solution was stored at −80°C.
SINV was propagated on BHK-21 cells. Similar procedures were followed for
preparation of SINV except where noted. After cells were inoculated with SINV, infected
cells were incubated for two days until the cells lysed. The cells were scraped without
freezing and clarified. Clarified SINV solution was stored using 10% glycerol and kept in
-80⁰C until further use for experiments [120].
Virus quantification was done using the colorimetric cell viability assay, the MTT
assay, as described earlier [120]. This assay determines the concentration of infectious
virus needed to maintain a 50% cell viability. For PPV, PK-13 cells were seeded in a 96well plate at a cell density of 8×105 cell per well and for SINV, BHK cells were seeded at
a cell density of 5×105 cells per well. Plates kept in an incubator for 24 hours and infected
with samples to be analyzed. Typically, the samples were diluted 5-fold across the 9629

well plate. After incubation (5 days for PPV, 2 days for SINV) 10 µl/well of 5 mg/ml
MTT solution (tetrazolium salt (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) in PBS was added to the plates. After 4 hours the solubilizing agent (0.01 M
HCl and 10% SDS in water) was added and plates were incubated overnight. The ddition
of MTT solution forms purple color formazan inside the mitochondria of metabolically
active cells and the addition of solubilizing agent solubilize this formazan. Upon
dissolving the formazan crystals, the cell viability was quantified by measuring the
absorbance of the solution at 550 nm using a Biotek Synergy Mx plate reader (Winooski,
VT). The virus infectivity was calculated using the MTT50 50% infectious dose value
which can be determined based on absorbance values of infected cells, as described
earlier by Heldt et.al [120]. So for this analysis, we grow cells in 96 well plates and infect
cells in serial dilution manner with the collected virus sample from experiments. After
infection and incubation MTT solutions mentioned above are added. Based on 50% dose,
the absorbance values are recorded for average uninfected cell wells. This reflects the
infectivity in terms of logarithmic factor based on dilution factor. The majority of
analysis was performed using 5-fold series dilution in 96- well plates, and for high titer
values 10- fold series dilutions were used.

3.3.

Virus Flocculation and Diafiltration

1M mannitol in NanoPure water was prepared fresh for every experiment to avoid
dissolution. For flocculation of virus particles with osmolytes, 9720 µl of mannitol and
405 µl of virus (PPV and Sindbis at 6 log MTT50/ml in PBS, unless stated otherwise)
were mixed and kept for 2 hours at room temperature with manual rotation every 15
minutes. This 1M concentration and ratio of osmolyte to the virus was adapted from our
previous studies in which we used 720 µl osmolyte with 30 µl of the virus [6, 7]. As a
control, a water and virus mixture were also prepared and kept for 2 hours. The ratio of
solutions was kept the same for all experiments with enveloped and non-enveloped virus.
Flocculated virus with osmolyte solution was filtered using a batch diafiltration
method as shown in Figure 3-1. A 10 ml Amicon filtration cell filter (Model 8010), a gift
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from EMD Millipore, was equipped with different pore size membranes. The membranes
were Durapore Membrane Filter PVDF 0.2 μm and 0.1 µm and BioMax’s
polyethersulfone (PES) 500 kDa and 300 kDa MWCO membranes, also gifts from EMD
Millipore. All membrane size were 25 mm and fits in filter holder of Amicon cell filter
model 8010. Filtration cells were operated at 10 psi pressure, unless otherwise stated,
from a compressed nitrogen tank and without stirring as stirring could break the
flocculated particles. Initially, 10ml of mannitol and virus solution was added to the
filtration cell, and pressure was applied until 2-3 ml of filtrate was collected, with 2 ml
being held up in the outlet tubing. This was the first fraction collected for filtrate (Filtrate
1 or F1). A 300 µl sample was removed from the retentate and labeled retentate 1 (R1).
After collection of the first fraction, 5 ml of 1M mannitol was added to make a total of 10
ml solution in the filter unit. The pressure was applied to the filtration cell unit and the
second fraction was collected. Similarly, for the third fraction, 5 ml of mannitol was
added and filtrate (F3) and retentate (R3) were collected immediately. The diafiltration
method is illustrated in Figure 3-1. As a control, the same procedure was applied using
water instead of mannitol and all samples were analyzed by titration using an MTT assay
mentioned earlier in section 3.2.
As we are adding more diavolumes to the diafiltration for collecting second and third
fractions, the addition of more osmolyte solution may be causing breaking of flocs, to
solve this problem we decided to perform flocculation time studies in between the
fractions. In flocculation time studies, after addition of osmolyte, we allowed settling the
virus and osmolyte solution more time prior to filtration. All samples collected were
analyzed using the MTT assay.
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Figure 3-1 Batch diafiltration setup for recovery of infectious virus particles using filtration cell
with manual addition of virus and mannitol, samples collected in three fractions with 5ml
addition of mannitol at 2nd and 3rd fraction

We also explored different concentrations of infectious virus particles as a starting
material for flocculation. A variety of starting concentrations were analyzed using the
same parameters as stated earlier with diafiltration. Mannitol solution for all samples was
prepared in water at 1M concentration unless otherwise stated. For the high concentration
titer solutions (log 11 MTT50/ml for PPV and log 10 MTT50/ml for SINV), 1M mannitol
was prepared in virus solution instead of water to avoid dilution of virus concentration
taking measured quantity of mannitol powder dissolved into virus solution.
All the results obtained through MTT assay gave the titer values for each collected
samples. The MTT50/ml values were converted into mass per MTT based on the volume
of samples. The step yield of infectious virus particles was calculated at each fraction of
retentate with respect to input at each fraction as shown following equations i.
𝑀𝑎𝑠𝑠 𝑝𝑒𝑟 𝑀𝑇𝑇 𝑓𝑜𝑟 𝑟𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑖
𝑌𝑖 = (
) × 100
𝑀𝑎𝑠𝑠 𝑝𝑒𝑟 𝑀𝑇𝑇 𝑓𝑜𝑟 𝑖𝑛𝑝𝑢𝑡 𝑖𝑛 𝑖 𝑡ℎ 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛

(i)

Where Yi represents step yield in the fractions, where i starting from 1. Step yield
calculations were performed considering input at each fraction as we are removing some
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quaintly from retentate for the analysis thus reducing the number of particles in each
input. All percent recovery values for each experiment were averaged over repeated
experiment to get more accurate data. After calculation of step yield at each fraction,
overall yield was calculated based on step yield for 2nd and 3rd fraction as described
earlier in equation (i), where for 2nd fraction it will be i+1, and for 3rd fraction i+2.
Recovery for first remains the same for unit yield calculations, and overall yield
calculations were performed using equation (ii).
𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑌𝑖+1 = 𝑌𝑖+1 × 𝑌𝑖

3.4.

(ii)

HPLC C-18 Chromatography

The samples collected from diafiltration using the 0.1 µm filters for PPV were
analyzed for purification using reverse phase chromatography (RP-HPLC). A Waters
XBridge BEH C18 Column 4.6 mm × 150 mm was used for samples analysis on a
Waters® e2695 HPLC equipped with a Waters 2998 Photodiode array detector UV/Vis
spectrophotometer detector. A sample volume of 10 µl was injected onto the column, and
all the samples were run at the same conditions. The mobile phase used for started at
100% buffer A, comprised of 0.1% TFA in water, and an increasing buffer B, comprised
of 0.1% TFA in acetonitrile. The flow rate for all samples was maintained at 0.500
mL/min, a sample temperature of 15°C and a column temperature of 25°C. The column
was washed in between samples using 100% acetonitrile. The area under the peak was
analyzed using Empower software which uses the numerical integration method using
trapezoidal rule equation (iii).
𝐴𝑟𝑒𝑎 𝑢𝑛𝑑𝑒𝑟 𝑡ℎ𝑒 𝑐𝑢𝑟𝑣𝑒 = (𝑡2 − 𝑡1 ) [

𝑓(𝑡1 )+𝑓(𝑡2 )
2

]

(iii)

Where t1 and t2 are the time range for chosen peaks with respect to UV absorbance
value at that times. Using the area under the curve, we further calculated percent removal
of peak area in different peaks using equations (iv) and (v) where ABF represents area
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under the curve of before filtration sample, AF1 for filtrate F1, and AR1 for retentate R1
sample.
𝐴𝐵𝐹 −𝐴𝐹1

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑖𝑛 𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑒 𝐹1 = (

𝐴𝐵𝐹

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑖𝑛 𝑅𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒 𝑅1 = (

3.5.

) ∗ 100

𝐴𝐵𝐹 −𝐴𝑅1
𝐴𝐵𝐹

) ∗ 100

(iv)
(v)

DNA Quantification

DNA quantification was done using the Quant-iT PicoGreen (Invitrogen, Eugene,
OR) dsDNA reagent. All the samples collected from diafiltration were analyzed for
dsDNA contents. For PPV and SINV infectious particles recovery, diafiltration was done
using 0.1 µm pore size filter, and concentration of PPV and SINV used at log 8
MTT50/ml. At lower concentration of log 6 MTT50/ml for PPV and SINV, we were
unable to detect DNA content as it was below detectable threshold levels. For preparing
all PicoGreen reagent 10mM Tris-HCL1 1mM EDTA buffer (TE Buffer) was used at pH
7.5. A standard curve was obtained using Lambda DNA standard at 2 different range of
standard 1 ng/mL to 1 μg/mL and 25 pg/mL to 25 ng/mL so as to detect even low
concentration of DNA contents. PicoGreen reagent and DNA standard are diluted using
TE buffer. All reagents prepared in a plastic container rather than glass as reagent may
absorb to a glass surface and also protected from light using aluminum foil as reagents
are light sensitive. The lambda DNA standard, given at 100 μg/mL concentration in the
kit, dilute it to 50-fold in TE buffer to make the 2 μg/mL as base solution. This 2 μg/mL
is diluted in series and used for standard curves. Then added aqueous working solution of
Quant-iT PicoGreen reagent to each well of 96-well plate along with standard DNA
samples and unknown samples from diafiltration. After mixing well and incubating for 25 minutes at room temperature protected from light, 96-well plates were read at
fluorescein wavelengths (excitation ~480 nm, emission ~520 nm) with a fluorescence
microplate reader Synergy Mx plate reader. Calculations for our samples DNA
quantification was performed using slope equation of standard curve for both standard
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range and low concentration range also. Removal of DNA content per step in retentate
samples was calculated using equation (vi).
𝐷𝑁𝐴 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑟𝑒𝑡𝑒𝑛𝑡𝑎𝑡𝑒

𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑜𝑓 𝐷𝑁𝐴 = (1 − (𝐷𝑁𝐴 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑖𝑛𝑝𝑢𝑡 )) × 100
(vi)
DNA removal at each fraction was calculated using equation (vi) and input at each
fraction was taken into consideration the amount of sample removed for analysis to get
more accurate results over each fraction.

3.6.

Transmission Electron Microscopy

For studying flocculation of PPV with mannitol, TEM imaging of flocculated and
non-flocculated samples were taken. Samples prepared as a mixture of 1M mannitol with
PPV (720 µl mannitol and 30 µl PPV at log 6 MTT50/ml and similarly with water with
PPV (720 µl water and 30 µl PPV at log 6 MTT50/ml) and allowed for flocculation for 2
hours. Flocculated virus samples were then inactivated before imaging for safety purpose
using 0.5% glutaraldehyde for 1 hour [121]. Samples were mounted directly on copper
grids (EMS200-Cu, Electron Microscopy Sciences) using 10 µl sample with micropipette and air dried overnight. Grids were washed in nanopure water and then stained in
droplets of 2% uranyl acetate on the parafilm wax paper for 2 minutes. Grids were
washed again after staining with pure water to prevent contamination. TEM images were
captured on a JEOL JEM-2010 (Peabody, MA) and imaging was done at 80 kV and
30000x magnification and 40000x magnification.
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4. Results and Discussion
To develop a platform approach, we have selected non-enveloped PPV and
enveloped SINV as model viruses to explore the potential of flocculation as a universal
platform virus purification process. Our previous work has demonstrated that a range of
osmolytes such as alanine, glycine, trehalose, mannitol successfully flocculate viruses
and not model proteins. This is likely due to preferential hydration that causing virus
aggregation. From the screened osmolytes, 3 M glycine was able to remove 96% PPV
particles, and 1 M mannitol showed >80% PPV removal [6]. We also showed mannitol
flocculation for enveloped SINV particles was able to achieve 96% removal at a mannitol
concentration of 0.3 M [7]. From this work, in an effort to develop a novel virus recovery
and purification process we decided to pursue flocculation with mannitol as it worked for
both model enveloped and non-enveloped virus systems. We are using mannitol at
optimal 1M concentration to work with both PPV and SINV virus purification and
recovery.

4.1.

Recovery of Non-Enveloped Porcine Parvovirus (PPV)

4.1.1. Overall recovery of PPV using different filter pore size
The first parameter studied was with different filter pore size. PPV is a small
mammalian virus with a diameter of 18-24nm [13, 14]. The screening work demonstrated
that PPV could be withheld with a 0.2 μm filter. However, since we wanted high
recoveries for such a small virus, we decided to start with the largest pore size of 0.1 μm.
The results are shown in Figure 4-1-A. The largest pore size was able to obtain a
recovery of 58% and the smallest pore size, a 300 kDa MWCO membrane, was able to
recover 85% of the infectious particles, demonstrating that as the pore size was reduced,
the recovery increased. Both pore sizes showed a significant difference from the water
negative control as smaller virus particles of PPV in water were able to pass through the
membrane pores, but mannitol caused flocculation to allow the virus to be withheld by
the filter. For the 500 kDa MWCO membrane, the negative control recovery was not
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significantly different from the mannitol recovery. This could be due to self-aggregation
of viruses in that batch during virus production based on the contaminant concentration in
specific batches. High contaminants in virus stock may cause HCP aggregates and pore
plugging in control studies. We also measured the amount of virus in the filtrate, and the
mass balanced closed. Therefore, there was no indication that the virus was absorbing to
the membranes or the filter housing.

Figure 4-1 Recovery of porcine parvovirus using different pore size filters. A: Comparison of the
recovery of PPV using 1M mannitol and the negative control water. B: Step yield of retentate
samples for flocculation with 1M mannitol after each batch diafiltration fraction. Details are
shown in Figure 3-1. Error bars are the standard deviation of three separate trials *p<0.05

To explore the ability of this system to recovery infectious in diafiltration mode,
we did additional batch fractions by adding pure mannitol to replace the filtrate volume.
This is shown in Figure 4-1-B. Each fraction remained at a consistent recovery except
for the smallest pore size, where the 2nd and 3rd fraction dropped due to disturbances in
the filtration unit while adding more mannitol. As we are adding more mannitol to
system, we are filtering immediately, this allows very less time for osmolyte flocculation
for interaction. As the aggregates are temporary manual disturbances in system breaks
aggregates and smaller virus particles are passing through the membrane.
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4.1.2. Flocculation time effect
To increase the recovery of the 2nd and 3rd fractions, we increased the incubation
time. The flocculation time of the first fraction was set at 2 hours due to the 2 hours
quiescent time that was used in the original screening work [6, 7], but the subsequent
fractions were only given 5 minutes from the addition of mannitol until the filtration. Our
previous work also demonstrated that the flocs are sensitive to shear stress [6, 7].
Therefore, it was hypothesized that the filtration immediately after mannitol addition
could have broken the flocs from the shear stress of mixing. We increased the filtration
time as shown in Table 4-1. The times were randomly chosen to minimize waiting time
and to optimize experimental duration as no previous studies had been performed on the
time effect of osmolyte flocculation. The results of increasing the time can be found in
Figure 4-2. There was not a significant difference between the recovery of PPV at the 0.1
µm filter size. However, the averages vary due to the large error that is found in the MTT
assay used to measure these values.
Table 4-1 Flocculation time effect between fractions of diafiltration for PPV

Fraction

Original diafiltration timea

1st fraction
2nd fraction

2 Hours
Immediate fraction collection after
addition of mannitol
rd
3 fraction
Immediate fraction collection after
addition of mannitol
a
Diafiltration time in Figure 4-1.

Increased diafiltration
time
2 Hours
45 minutes flocculation time
30 minutes flocculation time

As a control study, the PPV solution was flocculated with water instead of mannitol
(data not shown). Control study results show that there is no difference in the recovery
with normal flocculation and timed flocculation study and the overall recovery is 16% in
the first fraction with water as flocculation agent. In conclusion, we did not observe a
significant difference in PPV recovery with increased hold time between fractions. We
saw in the figure 4-1 that addition of more mannitol gives very little improved recovery
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(no statistical difference) and allowing time between fraction shows less difference in
significant flocculation effect. In future allowing higher time for flocculation in between
fraction can be tested to see does it help in aggregation.

Figure 4-2 Flocculation time effect in between the fractions during diafiltration using a 0.1 µm
pore size membrane for PPV, Comparative study of step yield of PPV with original diafiltration
time (green columns) and increased flocculation time (red columns) using 1M mannitol
flocculation. Error bars are the standard deviation of three separate trials.

4.1.3. Recovery of PPV with different starting concentration
To study the effect of the starting material concentration on flocculation, we
explored different initial PPV concentrations, and the results can be seen in Figure 4-3.
All the diafiltration experiments were carried out at a back pressure of 10 psi, however,
for the log 11 MTT50/ml, the pressure required for a system for flow-through was 30 psi.
This indicates that there was membrane fouling at the higher PPV concentrations as flux
is decreased. Results from this study show that using a starting material concentration of
log 9 MTT50/ml increases the recovery of PPV in the retentate as compared to previous
experiments with log 6 MTT50/ml starting concentration.
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We also explored the recovery of different diafiltration fractions, shown in Figure 43-B. Even though no wait time was given for the flocculation, the recoveries remained
similar to the first fraction.

Figure 4-3 Recovery of porcine parvovirus with different starting PPV concentrations as log 6,
log 9 and log 11 MTT50/ml with diafiltration experiments, the filter used for all experiments is 0.1
µm. A: Comparative percent recovery with mannitol and control water for 1st fractions. B: The
step yield using 1M mannitol and PPV with different concentration for all collected fractions
during diafiltration. Statistical difference is calculated using Avona factor between mannitol and
water 1st fractions, *p<0.05. Error bars are the standard deviation of three separate trials.

4.1.4. Purification of PPV
The protein content of samples after diafiltration was analyzed using HPLC reverse
phase chromatography on the C18 column. As we perform the diafiltration, the impurities
from serum proteins present in the cell culture media are hypothesized not to be affected
by mannitol flocculation. Thus after filtration, the impurities will pass through the filter
and the retentate should contain the virus and a lower concentration of serum proteins.
Since the total serum protein content was low to begin with, we used reverse phase
chromatography to measure the protein content. In Figure 4-4 we can see the
chromatographs for PPV flocculated with mannitol before filtration, after filtration, and
the PPV retentate. We performed this study in duplicates for each sample to make sure to
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minimize any error in sample eluting. From the chromatographs, we can see that before
filtration and filtrate are showing 2 major peaks while retentate graph has no major peaks.
The analysis shows that with diafiltration, we are able to purify the retentate from the
bovine serum albumin which is coming from the fetal calf serum in the completed media.

Figure 4-4 Purification of PPV using diafiltration. Reverse phase chromatography using C-18
column of the diafiltration samples collected with 0.1 µm pore size membrane before
filtration(purple), after filtration (dashed orange), and retentate (dotted green) with buffer A as
0.1% TFA in water and eluting buffer B as 0.1% TFA in acetonitrile (dotted blue line).

Further, we also determined the area under the curves of the peaks in the
chromatograms to calculate the percent removal of impurities using equation 3.8. The
area under the curve was taken from area integration calculation from the Empower
software that controls the HPLC. With our calculations, the percent removal of impurities
in the retentate PPV sample was found out to be 85% as compared to the before filtration
sample. This is an acceptable result for a single diafiltration pass. We are able to get good
recovery and high purification as recovery above 30% is acceptable standard in the
industries [101]. More purification may be possible with the additional diafiltration
fractions. With the successful recovery of infectious PPV particles and purification from
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HCP, this is a good ground for future work to setup a prominent downstream processing
using osmolyte flocculation and microfiltration.

4.1.5. DNA quantification for PPV
DNA quantification was performed on all the diafiltration collected samples before
filtration and after filtration samples were analyzed to see whether flocculation with
osmolytes helps to remove the host cell DNA contents from virus particles. Results show
in Figure 4-5 that the negative water control is able to remove more DNA than mannitol
flocculation. Therefore, the osmolytes likely flocculate the DNA. DNA removal for PPV
was about 45% in the first fraction and less than 7% DNA removal in next fractions due
to the addition of mannitol flocculated DNA remaining from the previous step. While in
the case of water, as there is no flocculation mechanism occurring it was not affecting the
DNA content and it was showing DNA content removal >60% in 1st fraction and about
40% in each next fractions. This was due to flushing out the DNA from the retentate.

Figure 4-5 DNA quantification for PPV. Percent removal of DNA in retentate samples for PPV
by mannitol flocculation using Picogreen DNA quantification. All samples collected using 0.1
µm filter pore size membrane and titer log 9 starting material for diafiltration. Error bars are the
standard deviation of two separate trials
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4.1.6. Overall PPV Recovery
The overall summary for the purification and recovery of PPV is shown in Table
4-2. This data shows that in the retentate samples, we were able to retain high PPV titers,
however, we did not concentrate the virus particles. Concentration would have been
expected since the volume of each retentate samples is reduced by half. Recovery
increases with each fraction for the water control because the starting titer of each unit
drops. The overall recovery includes all fractions earlier. It can be seen that the overall
PPV recovery after 3 fractions with the 0.1 um filter is not statistically different from the
water control, but the titer is a little higher. For the smaller pore size filters, it is even
more pronounced. More work is needed to improve the recovery of the virus in later
fractions. As shown previously, the DNA removal with mannitol flocculation found was
low because mannitol is likely flocculating DNA during diafiltration. As DNA are
charged particles, reasonable explanation for DNA being aggregated in presence of
mannitol can be the reduction of electrostatic forces due to mannitol. This leads to DNA
being aggregated and retained above membranes in retentate. Protein recovery was
calculated from reverse phase chromatography and shows an 85% protein removal which
comes from the cell culture media used in the virus preparation.
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Table 4-2 Overall recovery and purification of PPV,. Comparison of concentrations before and
after diafiltration, step yield, overall recovery with different filter pore size using diafiltration for
PPV recovery along with DNA removal and protein removal for mannitol
PPV
Filter
pore
size

DNA
removala
(%)

Protein
removalb
(%)

Starting
concentration
(MTT50/ml)

45

85

6.63 ± 0.1

500
kDa

-

-

6.93 ± 0.5

300
kDa

-

-

6.47 ± 0.2

0.1 µm

Flocculation with mannitol
Final retentate
Step yieldc
concentration
(%) by
(MTT50/ml) by
fractions
fraction
1st
6.35 ± 0.2
58 ± 19
2nd 5.75 ± 0.3
37 ± 20
rd
3
5.47 ± 0.4
52 ± 17
1st
6.70 ± 0.5
60 ± 14
nd
2
5.29 ± 0.4
43 ± 17
3rd
5.94 ± 0.6
53 ± 22
st
1
6.55 ± 0.2
85 ± 11
2nd 6.06 ± 0.1
57 ± 33
rd
3
5.86 ± 0.1
58 ± 16

Overall
recoveryd
(%) by
fraction
58 ± 19
21 ± 15
10 ± 9
60 ± 14
25 ± 8
11 ± 1
85 ± 11
53 ± 31
36 ± 22

Negative control flocculation with water
6.60 ± 0.2
1st
5.84 ± 0.2
17 ± 2
17 ± 2
2nd 5.43 ± 0.3
44 ± 22
7±2
3rd
5.29 ± 0.3
77 ± 27
7±4
st
7.04 ± 0.7
1
6.68 ± 0.8
43 ± 9
43 ± 9
500
kDa
2nd 6.01 ± 0.7
23 ± 14
9±3
3rd
5.09 ± 0.5
29 ± 3
2±1
st
6.61 ± 0.4
1
5.96 ± 0.3
20 ± 9
20 ± 9
300
kDa
2nd 5.64 ± 0.3
55 ± 31
12 ± 11
3rd
5.44 ± 0.3
81 ± 24
8±3
Error bar are standard deviation from three trials.
a: Based on Quant-iT PicoGreen dsDNA quantification method
b: Based on area under the curve calculations from reverse phase chromatography (RPC)
c: Based on infectious particles titer calculations using MTT50 assay for step yield calculations
from equation 3.1-3.3
d: Based on infectious particles titer calculations using MTT50 assay overall recovery calculation
from equation 3.1, 3.4 & 3.5.
0.1 µm

63

0
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4.2.

Recovery of Enveloped Sindbis Virus

4.2.1. Recovery of SINV using different filter pore size

For the recovery of enveloped SINV, experiments were carried out using 1M
mannitol flocculation followed by diafiltration. We started the diafiltration study with a
0.2 µm pore size filter and then studied smaller pore size filters. As the size of SINV is
about 50nm [14, 44], we want to accomplish high recovery using as large pore size filter
as possible. While in the case of PPV, we started with 0.1 µm pore size filter because of
the small size of PPV. Figure 4-6-A showing percent recovery for SINV in the first
fractions of retentate using different pore size membrane filters with mannitol
flocculation and water as control. Recovery of infectious SINV particles using 0.2 µm
filter shows 65% with mannitol. Using 0.1 µm membrane for the same experiments
shows increased recovery of 77%. Further using smaller membrane of 500 kDa achieved
96% recovery of infectious virus particles in the retentate. A control study for all pore
size shows no significant recovery. When a 300kDa membrane was used, SINV was
withheld with the control water. Comparative study of different pore size shows an
increase in the recovery as we use smaller pore size filter, while control sample does not
show increased recovery. This demonstrates that recovery of particles is based on the
bigger flocs of viruses formed due to mannitol flocculation.
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Figure 4-6 Recovery of SINV using different pore size, using 0.2 μm, 0.1 μm, 500 kDa pore size
filter with diafiltration method, A: Percent recovery in 1st fraction of diafiltration retentate
samples for flocculation with 1M mannitol and control water for different membrane pore size. B:
The step yield in all fractions using mannitol flocculation for each filter membrane pore size.
Error bars are the standard deviation of three separate trials *p<0.05

Looking further into each fractions of diafiltration, Figure 4-6-B shows results for
all fractions along with different pore size membranes. Studies with 0.2 µm and 0.1 µm
show consistent recovery in all fractions with mannitol flocculation method. Smaller pore
size filter 500 kDa was used for diafiltration to achieve a high recovery of infectious
virus particles. With 500 kDa pore size filter, we performed diafiltration, and the
recovery of SINV particles was about 96% in the first fraction using 1M mannitol
flocculation. This is the highest recovery of SINV achieved using 3 different pore size
filters as 0.2 μm, 0.1 μm, and 500 kDa filters. After addition of more diavolumes 1M
mannitol to the retentate from the first fraction and performing filtration, in the second
fraction of retentate it is showing 67% recovery and 69% recovery in the 3rd fraction of
retentate as shown in Figure 4-6-B. As a control for study with all the three different
pore size filter, water is showing low recovery of infectious SINV, which suggesting that
water is not affecting the size or flocculation of virus particles at all. Comparing results
from Figure 4.6-A and 4.6-B, we can see that we are able to get high virus recovery with
mannitol flocculation as compared to water flocculation.
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4.2.2. Flocculation Time Effect
Similar studies as mentioned in previous section 4.1.2 for the non-enveloped virus
for flocculation time studies was carried out with enveloped SINV. Keeping all the
parameters for the study similar except the flocculation time in between the fraction. We
performed flocculation time studies using 0.2 µm filter pore size and compared results
with 0.2 µm diafiltration without additional waiting time during fractions. Time allowed
in between the 1st and 2nd fraction was 45 minutes and for 2nd and 3rd fraction time
allowed 30 minutes as shown in Table 4-3.
The ratio of the virus with mannitol or water and the initial flocculation time were
kept the same for both studies. The recovery of infectious SINV was 66 % in the 1st
fraction of retentate which is same as we have seen in normal flocculation study as shown
in Figure 4-7. After allowing more flocculation time before filtering the 2nd fraction, a
significant increase in recovery was observed. Improved recovery can also be seen in 3rd
fraction after allowing more flocculation time, however, there was no statistical
difference shown. While looking at the water control, it showed no effect of flocculation
time between fractions there was no significant rise when the flocculation before the 2nd
and 3rd fractions was increased (data not shown).
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Figure 4-7 Flocculation Time Effect in between fractions during diafiltration using 0.1 µm
MWCO for SINV with 1M mannitol. Comparative study of the step yield of SINV with normal
diafiltration (green) and allowing flocculation time in between the fractions (red), Error bars are
the standard deviation of three separate trials *p<0.05

4.2.3. Recovery of SINV with different starting concentration
Different starting material concentration log 6, log 9, log 10 MTT50/ml of SINV was
added for the flocculation experiments to study the effect of concentration for recovery of
virus particles. All experiments were performed using a 0.1 µm membrane filter to have
the same comparison across all concentration range and with PPV. Using a higher
concentration of SINV for log 10 MTT50/ml shows there is significant membrane fouling
with low throughput at the membranes and pressure required for the system is about 30
psi, while for the lower concentration of log 6 and log 9 MTT50/ml and SINV pressure
required for the system is 10 psi.
Figure 4-8-A shows the percent recovery of SINV using different initial
concentration for mannitol and the negative water control. First fractions with mannitol
using log 9 MTT50/ml SINV concentration showed 79%. Increasing concentration to log
10 MTT50/ml we are able to get 90% recovery of SINV. No significant high recovery was
observed with the negative control, except for the log 11 MTT50/ml. Note that the
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membrane fouling that occurred at high concentration of virus, causing partial recovery
with the water control.

Figure 4-8 Recovery of SINV showing different starting concentration as log 6, log 9 and log 10
MTT50/ml with diafiltration experiments, A: Overall yield of SINV in presence of mannitol and
control, B: Step yield for SINV showing all 3 fractions recovery in presence of mannitol only.
Membrane filter used for all experiments is 0.1 µm, Error bars are the standard deviation of three
separate trials *p<0.05

Further details into each fraction of mannitol flocculation samples are shown in
Figure 4-8-B. Results with log 6 MTT50/ml SINV concentration were explained
previously in section 4.2.1. Using log 9 MTT50/ml of SINV shows 79% recovery in first
fraction which is about the same for log 6 MTT50/ml concentration for SINV. In the 2nd
and 3rd fraction recovery is 44% and 49% respectively due to braking of aggregates in
manual addition. Increasing the initial concentration of SINV to log 10 MTT50/ml and
1M mannitol without diluting in water, higher recovery was recorded. In the 1st fraction
recovery of 90% achieved followed by consistent recovery in each subsequent fractions.

4.2.4. Purification of SINV
For the diafiltration of SINV, we collected fractions of filtrate, retentate and
compared with before filtration samples for the purification validation using reverse
phase chromatography (RPC) using C18 column. As we hypothesis, we expected HCP
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will pass through the membrane after flocculation and microfiltration and purified SINV
should be retained. Several repeated HPLC analysis for the SINV diafiltration
experiment, it was not showing high purification. The total protein concentration in the
SINV preparations was very low because the virus was stored in glycerol during freezing.
We had to remove the glycerol with dialysis prior to HPLC, but it also removed many of
the contaminating proteins. The graphs in Figure 4-9 showing the chromatographs of
before filtration sample, filtrate sample and retentate. The before filtration sample shows
contaminant BSA peak at time 20-21 minutes (second peak on the continuous line curve),
filtrate is showing reduced contaminant while retentate has the contaminant BSA peak
(green dotted line curve). Area under the curve calculations shows that we were able to
remove about 37% of contaminant in the retentate sample, but starting concentration of
protein content was very low. To overcome low detectable values for HCP, we prepared
samples with added impurities (conditioned media as representative for HCP) and still
analysis was unable to get proper purification data. While in case of PPV purification,
we demonstrated 80% contaminant protein removal using same diafiltration experiment
with 1M mannitol.

Figure 4-9 Purification of SINV analysis using Reverse phase chromatograph using C-18 column
of the diafiltration samples before filtration(purple), after filtration (dashed orange), and retentate
(dotted green) with buffer A as 0.1% TFA in water and eluting buffer B as 0.1% TFA in
acetonitrile (dotted blue line)

50

4.2.5. DNA Quantification
In case of SINV diafiltration experiments, all collected fractions were analyzed
for DNA content for DNA removal. Samples collected from mannitol flocculation
demonstrate partial flocculation of DNA in first fraction as removal is about 50%, as
shown in Figure 4-10 but further addition of mannitol decreased removal of DNA.
Samples with water as control showing higher removal than with mannitol. So addition of
water is not affecting DNA removal, while addition of mannitol has opposing effect on
DNA removal. Mannitol flocculation was flocculating DNA also so we were unable to
get high removal of DNA in retentate. As DNA are charged particles, possible
explanation for DNA being aggregated in presence of mannitol can be the reduction of
electrostatic forces due to mannitol. To solve this problem and achieve better DNA
removal during diafiltration we would like to further study using benzonase endonuclease
treatment as several literatures have shown DNA removal using benzonase endonuclease
[86, 122]. We can use this endonuclease for removing DNA content from our virus
samples prior to flocculation and filtration which is effective method for removing DNA
as a future work.

Figure 4-10 DNA quantification for SINV . Percent removal of DNA in retentate samples for
SINV by mannitol flocculation using Picogreen DNA quantification. Diafiltration performed
using 0.1 μm membrane with log 9 SINV concentration. Error bars are the standard deviation of
two separate trials
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4.2.6. Overall Summary for enveloped SINV
Looking at the overall recovery and purification for SINV, Table 4-3 shows the
comparative data for DNA removal, protein removal, concentrations and recovery by
fractions. DNA quantification and protein removal study by reverse phase
chromatography was performed on samples collected by 0.1 µm membrane based
diafiltration. Concentrations in terms of MTT50/ml are showing the infectious virus titers
in each fractions of retentate samples. For samples from diafiltration using 0.1 µm, 500
kDa and 300 kDa membrane, with starting concentration of SINV, we can see in retentate
we are able to get high titer values close to starting concentration in first fraction and then
decreasing titer in next fractions. While our negative control shows drop in the
concentration of retentate after diafiltration.
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Table 4-3 Overall recovery and purification of SINV, Comparison of concentrations before and
after diafiltration, step yield, overall recovery with different filter pore size using diafiltration for
SINV recovery along with DNA removal and protein removal for mannitol
SINV
Filter
pore
size

DNA
removala
(%)

Protein
removalb
(%)

Flocculation with mannitol
Starting
Final retentate
concentration concentration
(MTT50/ml)
(MTT50/ml) by
fraction

0.2 µm
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37

6.43 ± 0.2

1st
2nd
3rd

0.1 µm

-

-

7.03 ± 0.8

500
kDa

-

-

6.07 ± 0.7

1st
2nd
3rd
1st
2nd
3rd

Step
yieldc
(%) by
fractions

Overall
recoveryd
(%) by
fraction

6.33 ± 0.5
5.95 ± 0.5
5.77 ± 0.5

65 ± 24
52 ± 24
58 ± 30

65 ± 24
45 ± 25
35 ± 20

7.10 ± 0.5
6.96 ± 01
6.64 ± 0.6
6.10 ± 0.7
5.89 ± 0.7
5.39 ± 0.7

77 ± 31
79 ± 20
72 ± 36
96 ± 5
67 ± 7
69 ± 3

77 ± 31
62 ± 24
45 ± 18
96 ± 5
71 ± 8
46 ± 2

Negative control flocculation with water
6.69 ± 0.2
1st 6.03 ± 0.5 20 ± 13
20 ± 13
2nd 6.20 ± 0.5 86 ± 22
32 ± 24
rd
3
5.77 ± 0.8 48 ± 27
20 ± 18
st
7.55
±
1
1
6.63
±
1
21
±
31
21 ± 21
0.1 µm
nd
2
6.50 ± 1
65 ± 26
22 ± 18
3rd
5.26 ± 1
76 ± 39
21 ± 24
6.95 ± 1
1st
6.35 ± 1
29 ± 16
29 ± 16
500
nd
kDa
2
5.66 ± 0.7 36 ± 28
11 ± 7
3rd 5.60 ± 0.9 74 ± 23
7±4
Error bar are standard deviation from three trials.
a: Based on Quant-iT PicoGreen dsDNA quantification method
b: Based on area under the curve calculations from reverse phase chromatography (RPC)
c: Based on infectious particles titer calculations using MTT50 assay for step yield calculations
from equation 3.1-3.3
d: Based on infectious particles titer calculations using MTT50 assay overall yield calculation
from equation 3.1, 3.4 & 3.5.
0.2 µm
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4.3.

Transmission Electron Microscopy

To support the flocculation hypothesis along with all the results shown earlier, we
performed imaging of the flocculated virus particles in osmolyte solution. In Figure 4-11
it is showing images for flocculated PPV in mannitol and in water as a control. Figure 411 A and B are showing that PPV particles in mannitol at two different resolutions.
Aggregates are easily found. The aggregate size around 100 nm is also supported by the
filtration results that below a 0.1 um filter, there is a rise in virus found in the retentate. In
comparison, images of PPV in water (shown in Figure 4-11 C and D) showed separated
and individual particles. This further supports the theory that mannitol is causing virus
flocculation.
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Figure 4-11 Transmission electron microscope images for PPV sample in mannitol and water.
Figure A (100 nm) & B (500 nm) shows PPV with mannitol, Figure C (100 nm) & D (500 nm)
showing PPV with water

4.4.

Discussion

To prove our hypothesis that mannitol flocculation works for all types of viruses and
can be applied as a novel platform approach with minimal changes, we studied the nonenveloped PPV and enveloped virus, SINV. For both viruses, osmolyte mannitol was
able to flocculation based on our results of virus retentions using large pore sixe filters.
Addition of mannitol, removes the bound water around the viruses due to preferential
hydration of osmolyte. Section 4.1, shows recovery and purification data for PPV. We
got 58% recovery using 0.1 µm filter for the PPV and highest recovery of 85% was
achieved using 300 kDa filter. In Section 4.2, we have shown all the results for recovery
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of SINV using different pore size filter such as 0.2 µm, 0.1 µm and 500 kDa filters.
Using 0.2 µm pore size filter we were able to obtain a 65% recovery in the first fraction
and 79% recovery using a 0.1 μm pore size filter. Highest recovery was achieved using a
500 kDa pore size filter which was 96%. As we are using different pore size filter,
recovery of infectious SINV particles was increasing with decreasing filter pore size.
Considering the size of SINV, which is about 50 nm, we are able to recover SINV
particles even with large pore size filter as 0.2 μm. As a control study and to show
mannitol is responsible for forming the flocs of virus. We also performed control studies
with water. As seen in our previous results from section 4.1 and 4.2, it is showing that the
percent recovery of virus particles is low or virus particles are passing though the filter
while performed with water.
This recovery using microfiltration is significantly promising as compared to the size
of virus. In literature review, we have seen studies for recovery of viruses using small
MCWO membranes such as 30 kDa, 50 kDa and 100 kDa for parvovirus MVM (22-26
nm size) [98] and Aedes aegypti densonucleosisvirus (20-30 nm) [91, 95]. While many
studies have used multiple step purifications using two chromatography techniques and
series or combination of chromatography and ultrafiltration as we saw in Table 2-3 and
Table 2-4. So comparing size of membranes used for retaining virus, we are able to retain
small virus using micro-filters. This can reduce the cost related to ultrafiltration in terms
of cost of membranes, pressure requirements for the system. Also using large pore size
membranes can reduce pore plugging due to small debris, protein contaminants blocking
the small pores of ultrafiltration membranes. In section 2.4, we have seen recovery and
purification of viruses using multiple chromatography steps. Using set of
chromatography was able to get high purity and product recovery was still moderate as
40% to 70% [65, 75,78, 80]. With ultrafiltration using small pore sized membranes
literature have shown moderate recoveries and used final polishing step such as
chromatography to get high purity [90, 92, 96, 98]. With our approach, we were able to
get moderate recovery using large pore size filters and high recovery with 300 kDa for
PPV. For SINV moderate recovery is seen with 0.2 μm filter, which is usually used for
larger particle filtration. In normal conditions, without virus flocculation 0.2 μm filters
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will not be able to retain small viral particles of size 50nm. High recovery was obtained
using 0.1 μm and 500 kDa filter. From our purification data, PPV purification was good
and acceptable as per industrial requirements [101]. While in industry or in literature
review we saw that high purification was achieved using multiple steps or combination of
different steps. Using osmolyte flocculation can be developed and used as a platform
approach. In terms of DNA removal, we can improve purity by using endonuclease
treatment to remove more DNA content from the virus retentate product [86, 122].
As we study and compare the results for no flocculation time between fraction with
increased flocculation time, we only observe an improvement in the recovery in the 2nd
fraction for SINV, while with PPV recovery, we are not getting any improvement.
Comparing the size of both viruses, PPV virus is a non-enveloped virus and has smaller
capsid while SINV is an enveloped and contains outer lipid layer. SINV is bigger in size
about 48-52 nm while PPV is the smallest parvovirus of size about 18-24 nm. The outer
layer of viruses could be the decisive element in effective flocculation with osmolyte as
the interactions for aggregations may change with the presence or absence of enveloped
bilayer on virus particles. As we are performing recovery of virus particles using larger
pore size filters the size of aggregated virus plays an important role.
While we are able to show advantage of using flocculation and microfiltration, we
anticipate some disadvantages to our process. We have seen that virus flocs are not
permanent and can be broken with disturbances or agitation in the mixture. It is both
good and bad for the system. It is good because after product recovery, we don’t have to
worry about breaking flocs with other treatment. Flocculated particles can be easily
dispersed in buffer such as PBS. It is not good for the recovery of viruses, as breaking of
flocs allows particles to pass through the membrane and reduces overall yield. We have
seen addition of mannitol for 2nd and 3rd fractions created disturbances in system and
recovery was reduced. This is an important factor for consideration while designing large
scale configuration for this approach it is important factor. Using large scale tank reactor
similar to Amicon filtration cells we have used and allowing quiescent time after addition
of virus and osmolyte for flocculation without disturbances in the system is
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recommended. Allowing dormant time at ambient temperature for flocculation can be
disadvantageous for some sensitive products which are susceptible to reduced activity at
room temperature.
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5. Conclusions and future work

5.1.

Conclusion

This work describes the purification of two viruses using a common, novel
flocculant, mannitol. As mannitol is currently used as therapeutic substance for treatment
in diuretic conditions, brain swelling conditions it is acceptable as biological drug and is
FDA approved [8, 9]. PPV being smallest parvovirus of size about 20-24 nm [13, 14], is
difficult to recover using filtration methods. However, with our novel approach of
flocculation using 1M mannitol, we were able to form flocs that could be removed with
larger pore size filters. Using a diafiltration method, we were able to recover infectious
particles in the retentate. We explored the effect of different pore size filters, ranging
from 0.2 µm to a 300 kDa MWCO filter. We have successfully shown that 58% of
infectious PPV can be recovered with a 0.1 µm filter and 65% of infectious SINV. The
PPV had an 85% reduction in contaminating proteins, while SINV had low protein
removal of 37%. We were able to get no significant improvement for the non-enveloped
PPV, and only a significant improvement can be seen in case of enveloped SINV for the
2nd fraction. Time is still a variable that may need further study. The flocculation process
was not able to get high removal of DNA content as it was also retained in the retentate
with virus particles. Compared to control studies, we can see that mannitol was
aggregating DNA content as well while in case of control study DNA content was
removed. We therefore propose to use benzonase to reduce the size of the DNA prior to
flocculation in order to inhibit DNA flocculation with mannitol. TEM images for PPV
flocculation provide good support to our theory and all work shown in this research.
Our recovery results show that mannitol flocculation followed by diafiltration is able
to recover an enveloped and non-enveloped virus and purify a non-enveloped virus. Our
platform approach can be used as a potential method to replace chromatography and
nanofiltration. This results can be used for future work and can be applied to large to
medium scale to develop an industrial processing protocol. Adding advantages over
replacing multiple traditional and expensive methods as chromatography or
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ultrafiltration, new platform approach can be an effective new method in new vaccine
production setups.
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5.2.

Future Work:

Currently, we have shown high recovery for an enveloped and non-enveloped virus
and purification for a non-enveloped virus using batch diafiltration. The traditional batch
diafiltration approach is applicable in lab scale models, but is not a good choice for
industrial scale. We would like to develop this diafiltration method into a continuous
process by incorporating continuous method with recycling of osmolyte solution.
Currently our setup for diafiltration includes manual addition of mannitol solution into
the filter unit. By using mannitol reservoir tank incorporated with pressure application, it
can be used in a continuous diafiltration mode. For improved recovery of viruses, we
would like to explore if we can change the hydrophobicity while performing the
flocculation step. Increasing the hydrophobic interactions by addition of ethanol to the
flocculation solution may affect the flocculation of viruses. Presence of polar group on
ethanol enhances the hydrophobic nature of ethanol and when added to virus solution it
should add effective hydrophobic forces on virus particles. Studies have shown increase
in hydrophobicity with increasing concentration of ethanol on membranes [123, 124]. To
overcome the current challenge for DNA removal, we can use benzonase treatment for
efficiently remove DNA content while performing diafiltration method for higher
purification. Benzonase nuclease is endonuclease enzyme which can degrade DNA and
RNA which are considered as contaminant from host cells [86, 122]. Our preliminary
data using benzonase nuclease treatment with PPV prior to flocculation and diafiltration
decreased the initial DNA content and showed high DNA removal (data not shown) as
compared to given results in section 4.1.5.
We are interested in trying both enveloped and non-enveloped virus flocculation
using another osmolyte, glycine, which has been demonstrated for virus removal in
previous studies in our lab [6] and show promise as a flocculant for both viruses. In
addition, we would like to perform flocculation experiments with different viruses such
as minute virus of mice (MVM) and phage MS2. In the future, we will focus on improved
purification and recovery of viruses by capture with charged anion membranes for
vaccine manufacturing. Using charged anion membranes can help for recovery based on
size of virus particles as well as surface charges of viruses. These membranes can be used
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in bind and elute mode, similar to standard chromatography, and would allow for better
clearance of impurities.
To develop this method as an acceptable platform approach, I would like to work on
creating large scale module for this method. Demonstrating that osmolyte flocculation is
easily scalable, this experiments can be performed at large scale of 400 ml. Using
continuous diafiltration method, removing the need to manual addition of osmolyte
system can work in continuous manner and more likely decrease the disturbances in
system which are responsible for breaking up the aggregates. More detailed results can be
obtained regarding membrane permeability, reflux effect, flow rate by using pressure
transducers, flow rate controllers for monitoring inlet to outlet pressure ratios, flow rate
changes in the system. This setup would be similar to the current filtration systems as
commercially available TFF or NFF systems with tank reactor operated in normal flow
direction or dead end filtration. Tank reactor for holding flocculation mixture with
replaceable filter membranes holder and standard tubing. The inlet and outlet will be
connected with inline pressure sensors to determine the change in efficiency of flow
across the membrane by monitoring pressure changes. Such systems are currently
common in industry for virus purification with TFF which are scalable from pilot plant to
large scale production. Instead of using multiple ultrafiltration filtration steps, we can
introduce flocculation and microfiltration setup.
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